http://www.sciencemag.org/news/2019/10/alzheimer-s-drug-resurrected-company-claims-clinical-benefits

In a surprise move, Biogen says it will press for U.S. approval to sell an Alzheimer’s drug candidate targeting toxic beta-amyloid (brown).

Biogen stunned investors and scientists alike today, announcing it will resurrect an Alzheimer’s drug it had declared a failure in March; the company plans in early 2020 to ask the U.S. Food and Drug Administration for marketing approval of aducanumab, an antibody designed to bind and eliminate the protein beta-amyloid in the brain.